- Home
- CRBP vs NMS Comparison
CRBP vs NMS Comparison
Compare CRBP & NMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- NMS
- Stock Information
- Founded
- CRBP 2009
- NMS 1993
- Country
- CRBP United States
- NMS United States
- Employees
- CRBP N/A
- NMS N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- NMS Finance Companies
- Sector
- CRBP Health Care
- NMS Finance
- Exchange
- CRBP Nasdaq
- NMS Nasdaq
- Market Cap
- CRBP 73.4M
- NMS 68.7M
- IPO Year
- CRBP N/A
- NMS N/A
- Fundamental
- Price
- CRBP $8.33
- NMS $11.36
- Analyst Decision
- CRBP Strong Buy
- NMS
- Analyst Count
- CRBP 10
- NMS 0
- Target Price
- CRBP $53.56
- NMS N/A
- AVG Volume (30 Days)
- CRBP 123.5K
- NMS 12.0K
- Earning Date
- CRBP 08-05-2025
- NMS 01-01-0001
- Dividend Yield
- CRBP N/A
- NMS 4.11%
- EPS Growth
- CRBP N/A
- NMS N/A
- EPS
- CRBP N/A
- NMS N/A
- Revenue
- CRBP N/A
- NMS N/A
- Revenue This Year
- CRBP N/A
- NMS N/A
- Revenue Next Year
- CRBP $150.03
- NMS N/A
- P/E Ratio
- CRBP N/A
- NMS N/A
- Revenue Growth
- CRBP N/A
- NMS N/A
- 52 Week Low
- CRBP $4.64
- NMS $9.21
- 52 Week High
- CRBP $61.90
- NMS $12.18
- Technical
- Relative Strength Index (RSI)
- CRBP 54.09
- NMS 45.28
- Support Level
- CRBP $8.10
- NMS $11.31
- Resistance Level
- CRBP $9.45
- NMS $11.49
- Average True Range (ATR)
- CRBP 0.52
- NMS 0.09
- MACD
- CRBP -0.08
- NMS 0.01
- Stochastic Oscillator
- CRBP 55.74
- NMS 50.00
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.